CG Oncology vs Curis
CGON and CRIS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGON and CRIS compare
CG Oncology is the larger company, worth 5203 times as much as Curis ($6.2B against $1.2M).
CG Oncology grew revenue faster over the last twelve months (184% versus −62.2% for Curis).
Curis keeps more of each dollar of sales as profit, with a net margin of −490% compared with −3851% at CG Oncology.
Curis scores higher on the StockData Score (7 against 5 for CG Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGON | CRIS |
|---|---|---|
| Size and price | ||
| Market cap | $6.2B | $1.2M |
| Share price | $70.15 | $0.572 |
| Change, 1 year | 80.6% | −97.7% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 1.36 | 1.90 |
| Employees | 142 | 24 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1008× | 0.3× (better) |
| P/B | 6.3× | 0.3× (better) |
| FCF yield | −3.0% | – |
| Fair value | – | $6.71 |
| Margin of safety | – | 91.5% |
| Growth | ||
| Revenue growth (TTM) | 184% (better) | −62.2% |
| Revenue growth, 5Y average | – | −2.7% |
| Profitability | ||
| Operating margin | −4294% | −203% (better) |
| Net margin | −3851% | −490% (better) |
| FCF margin | −3068% | – |
| Return on equity | −28.3% | – |
| Return on invested capital | −2103% | – |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 21.70 (better) | 0.49 |
| Altman Z-score | 66.48 (better) | −96.16 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −7.9% (better) | −2057% |
| Shareholder yield | −7.9% (better) | −2057% |
| Ownership | ||
| Held by institutions | 106% | 32.1% |
| Held by insiders | 17.3% | 20.4% |
| Insider net buying, 12 months | $20.0M (better) | $5.5K |
| Short interest, % of float | 12.6% | 61.8% |
Go deeper
- CGON stock overview
- CGON income statement
- CGON valuation and score
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.